Patented Medicine Prices Review Board Canada
Results and programs. GC InfoBase reports 8 programs of this department, in its Departmental Plans or its actual spending; 3 are current (in the latest plan or, for a program in no plan, with actual spending in the latest year).
- Actual spending, 2024-25
- $13.7M
- Planned, 2025-26 (latest plan)
- $32.5M
- Core responsibilities with indicators
- 2
Spending and employees
Totals of the department's programs: actual spending where reported, then the latest plan.
Spending
Show the numbers
| Fiscal year | Planned | Actual |
|---|---|---|
| 2010-11 | — | $9.5M |
| 2011-12 | — | $11.8M |
| 2012-13 | — | $8.1M |
| 2013-14 | — | $10.5M |
| 2014-15 | — | $7.9M |
| 2015-16 | — | $9.5M |
| 2016-17 | — | $10.1M |
| 2017-18 | — | $9.7M |
| 2018-19 | — | $10.3M |
| 2019-20 | — | $13.3M |
| 2020-21 | — | $15.3M |
| 2021-22 | — | $12.3M |
| 2022-23 | — | $12M |
| 2023-24 | — | $14M |
| 2024-25 | — | $13.7M |
| 2025-26 | $32.5M* | — |
| 2026-27 | $31.6M* | — |
| 2027-28 | $16.8M* | — |
| 2028-29 | $16M* | — |
Employees (FTEs)
Show the numbers
| Fiscal year | Planned | Actual |
|---|---|---|
| 2011-12 | — | 63 |
| 2012-13 | — | 60 |
| 2013-14 | — | 55 |
| 2014-15 | — | 56 |
| 2015-16 | — | 63 |
| 2016-17 | — | 64 |
| 2017-18 | — | 60 |
| 2018-19 | — | 66 |
| 2019-20 | — | 79 |
| 2020-21 | — | 80 |
| 2021-22 | — | 78 |
| 2022-23 | — | 77 |
| 2023-24 | — | 82 |
| 2024-25 | — | 78 |
| 2025-26 | 139* | — |
| 2026-27 | 139* | — |
| 2027-28 | 81* | — |
| 2028-29 | 81* | — |
Results at a glance
How many indicators met their target each year, as reported in the Departmental Results Reports. Source: GC InfoBase.
Core responsibility indicators
| Report year | Met | Not met | No result reported | Not yet due | Share met (of met and not met) |
|---|---|---|---|---|---|
| 2018-19 | 1 | 1 | 0 | 1 | 50% |
| 2019-20 | 1 | 1 | 0 | 1 | 50% |
| 2020-21 | 1 | 1 | 1 | 0 | 50% |
| 2021-22 | 1 | 1 | 0 | 1 | 50% |
| 2022-23 | 0 | 2 | 1 | 0 | 0% |
| 2023-24 | 0 | 1 | 2 | 0 | 0% |
| 2024-25 | 0 | 1 | 2 | 0 | 0% |
Program indicators
| Report year | Met | Not met | No result reported | Not yet due | Share met (of met and not met) |
|---|---|---|---|---|---|
| 2018-19 | 2 | 1 | 0 | 2 | 67% |
| 2019-20 | 3 | 0 | 0 | 2 | 100% |
| 2020-21 | 3 | 0 | 2 | 0 | 100% |
| 2021-22 | 2 | 1 | 0 | 2 | 67% |
| 2022-23 | 2 | 1 | 2 | 0 | 67% |
| 2023-24 | 1 | 2 | 2 | 0 | 33% |
| 2024-25 | 1 | 2 | 2 | 0 | 33% |
Results by core responsibility
Monitor Patented Medicine Prices (3 indicators)
Historical: targets against results
No results reported yet.
Current: the 2026-27 plan's targets
Number of months after the relevant calendar year that the PMPRB’s Annual Report is submitted to the Minister of Health
2026-27Target: ≤ 12 (2027)Result: —Planned
Percentage of rights holder filings monitored within the calendar year
2026-27Target: ≥ 95% (2027)Result: —Planned
Future goals: targets due after 2026-27
Percentage of Hearings completed within 24 months of the issuance of a Notice of Hearing
2026-27Target: ≥ 90% (2028)Result: —Planned
Regulate Patented Medicine Prices (3 indicators)
Historical: targets against results
% of patented drug prices in Canada are within the thresholds set out in the PMPRB’s Excessive Price Guidelines
2024-25Target: ≥ 95% (2025)Result: —No result reported
% of patented drug prices in Canada below the median price of the PMPRB’s comparator countries
2024-25Target: ≥ 50% (2025)Result: 37%Not met
% reduction in the number of patented drugs priced above the international median
2024-25Target: ≥ 0%Result: S.O.No result reported
Current: the 2026-27 plan's targets
No indicators in the 2026-27 plan.
Future goals: targets due after 2026-27
No targets with a later due date.
Programs
| Program | Core responsibility | Status | Latest plan, first year | Last actual | Indicators |
|---|---|---|---|---|---|
| Patented Medicine Price Monitoring Program · BYU02 | Monitor Patented Medicine Prices | New since an earlier plan | $11.3M 2026-27 | — | 2 |
| Internal Services · ISS00 | — | New since an earlier plan | $3.5M 2026-27 | $3.9M 2024-25 | 0 |
| Pharmaceutical Trends Program · BYU01 | Monitor Patented Medicine Prices | New since an earlier plan | $2.4M 2026-27 | — | 1 |
| Patented Medicine Price Regulation Program · BVM01 | Regulate Patented Medicine Prices | Appeared and later dropped | $12M 2024-25 | $7.6M 2024-25 | 3 |
| Patented Medicine Prices Regulation Program · ALE00 | Canadians are protected from excessive prices for patented medicines sold in Canada and stakeholders are informed on pharmaceutical trends. | Not in a Departmental Plan | — | $5.6M 2017-18 | 0 |
| Internal Services · ISC00 | Internal Services | Not in a Departmental Plan | — | $2.6M 2017-18 | 0 |
| Pharmaceutical Trends Program · BVM02 | Regulate Patented Medicine Prices | Appeared and later dropped | $2.3M 2024-25 | $2.2M 2024-25 | 2 |
| Pharmaceutical Trends Program · ALD00 | Canadians are protected from excessive prices for patented medicines sold in Canada and stakeholders are informed on pharmaceutical trends. | Not in a Departmental Plan | — | $1.5M 2017-18 | 0 |
